Effect of Dronedarone on Cardiovascular Outcomes in High-Risk Patients With Atrial Fibrillation or Atrial Flutter - ATHENA

Description:

ATHENA (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter) was a double-blind randomized clinical trial designed to test the safety and efficacy of dronedarone in the treatment of atrial fibrillation (AF) and atrial flutter (Afl).